Sign inCreate account

Report workspace tools

NCT07179653ACTIVE_NOT_RECRUITINGanonymous

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Sponsor

Source record

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

TVAX-008, Placebo

Indication / condition

AI-normalized

HBV Infection

Intervention

Source record

TVAX-008, Placebo

Source & freshness

Source record

NCT ID

NCT07179653

Original source

ClinicalTrials.gov

Source last updated

Sep 18, 2025

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07179653

Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Sponsor

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Condition raw

HBV Infection

Condition normalized

HBV Infection

Modality raw

small molecule

Modality normalized

small molecule

Target raw

TVAX-008, Placebo

Target normalized

TVAX-008, Placebo

Interventions

TVAX-008, Placebo

Public preview

Source record

The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07179653

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Sponsor

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Executive brief

Investment-Ready Snapshot

The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 18, 2025
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07179653

Indication

HBV Infection

Modality

small molecule

Target

TVAX-008, Placebo

Intervention

TVAX-008, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.